Similarly, a meta-analysis investigated the association between specific ceramide species and cardiovascular disease, finding that major adverse cardiovascular events (MACEs) were associated with elevated plasma concentrations of Cer (d18:1/16:0), Cer (d18:1/18:0), and Cer (d18:1/24:1), whereas levels of Cer (d18:1/22:0) and Cer (d18:1/24:0) were not similarly increased [105]. The gene discussed is CBLN1; the disease is cardiovascular disorder.